Brief: Glenmark Pharma- Receives FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution
20/03/2025 15:33
March 20 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMACEUTICALS - RECEIVES FDA APPROVAL FOR OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION Source text: ID:nBSE71jjXQ Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter